Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04417712
Other study ID # LT/TS/45CE-04-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 4, 2019
Est. completion date June 30, 2023

Study information

Verified date April 2024
Source Lifetech Scientific (Shenzhen) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is to collect real-world data on patient outcomes and evaluate the procedural success and performance of the Lifetech KONAR-MF™ VSD Occluder for patients with ventricular septal defect (VSD).


Description:

This is a non-randomized prospective post-marketing clinical follow-up study (PMCFS) in order to evaluate the feasibility and safety of the Lifetech KONAR-MF™ VSD Occluder device used for patients with ventricular septal defect. The implantation should be performed in accordance with the instructions for use (IFU).


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 30, 2023
Est. primary completion date March 30, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria: 1. Patients have a clinically relevant ventricular septum defect (VSD) by Echocardiography and/or X-ray examination according to current clinical standards and center-specific protocols. 2. The patient should be older than 6 months of age and a bodyweight heavier than 8kg. 3. Defect diameter (by 2D Echocardiography): The size of the VSD is larger than or equal to 2mm and less than 10mm. 4. Upper margin of VSD to aortic valve distance >2 mm for models 6-4, 8-6, 10-8, 12-10, 14-12 and >2.5mm for models 5-3, 7-5, 9-7, in case of PmVSD. 5. Only left to right shunt of the ventricular shunt. Exclusion Criteria: 1. Any contraindication mentioned in the corresponding IFU*. - Note: In IFU, contraindications for The KONAR-MFTM VSD Occluder are as follows: 1. Patient has extensive congenital cardinal anomaly which can only be adequately repaired by cardiac surgery. 2. Presence of thrombus at the intended site of implant, or documented evidence of venous thrombus in the vessels through which access to the defect is gained. 3. Active endocarditis or other infections-producing bacteria. 4. The implant of KONAR-MFTM VSD Occluder would cause an obvious interference with the aortic valve or the atrioventricular valve. 5. Patients with severely increased pulmonary vascular resistance and a right-to-left shunt and patients with documented irreversible pulmonary vascular disease. 6. Patients with contraindications to anti-platelet therapy or agents. 2. The patient does present with an aortic valve prolapsing into the VSD. 3. Currently participating in other investigational drugs- or device studies. 4. The patient who is pregnant, planning to become pregnant, or breastfeeding. 5. Patients don't give informed written consent for the procedure. 6. Patient with other cardiac anomalies by surgery therapy.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
KONAR-MF™ VSD Occluder
All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).

Locations

Country Name City State
Germany 103 - Herz- und Diabeteszentrum NRW / Heart and Diabetes Center NRW Bad Oeynhausen
Germany 101 - Deutsches Herzzentrum der Charité/ German Heart Institute Berlin Berlin
Germany 102 - Deutsches Herzzentrum München/ German Heartcenter Munich Munich
Italy IRCCS Policlinico San Donato Milan

Sponsors (1)

Lead Sponsor Collaborator
Lifetech Scientific (Shenzhen) Co., Ltd.

Countries where clinical trial is conducted

Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accurate success rate VSD closure without complication (dislocation, hemolysis, AVB, device-related valve dysfunction, thrombosis, infection, or endocarditis) and no or only mild residual shunt after 12 months of follow-up. From implant attempt to 12-month post-procedure.
Primary Procedure successful The optimal position of the VSD with appropriate closure rate at echocardiographic examination. No or only tiny or without residual shunt and absence of device-related aortic or atrioventricular valve reflux. From implant attempt to 12-month post-procedure.
Secondary Rate of device and procedure-related serious adverse events (SAE). Rate of device and procedure-related serious adverse events (SAE) during 12 months post-procedure. From implant attempt to 12-month post-procedure.
Secondary Rate of complete atrioventricular block (cAVB) or any arrhythmia needed for pacemaker implantation, device removal, or any kind of medical treatment. Rate of complete atrioventricular block (cAVB) or any arrhythmia needed for pacemaker implantation, device removal, or any kind of medical treatment in patients within 12 months post-implantation. From implant attempt to 12-month post-procedure.
Secondary Rate of incomplete closure at the 12-month follow-up. Rate of incomplete closure at the 12-month follow-up: significant shunt will be defined as = moderate or indicating treatment (surgical or interventional). The residual shunt will be defined by color Doppler echocardiography and will measure the shunt size according to prior published classification. At 12-month follow-up.
Secondary Rate of device deficiencies. Rate of device deficiencies (including device malfunction, failures, and non-conformances) during 12 months post-procedure. From implant attempt to 12-month post-procedure.
Secondary Incidence within 12 months post-implantation Incidence within 12 months post-implantation for:
Hemolysis including any drop in hemoglobin (Hb) of >2.5 g/dl within 24 hours and Severe acute hemolysis, which is defined as Hb =5 g/dl or received blood transfusion according to the clinical judgment of the study physician.
Hemolysis can be excluded by sample urine within 24 hours post-implantation. If hemolysis might be suspected, blood sampling (blood count incl. hemoglobin) should be initiated according to SOP or clinical practice.
Thromboembolism: thrombosis of device or vascular access that requires thrombolytic therapy;
Migration of the occlude requiring device removal;
Embolization of the occluder requiring device removal.
From implant attempt to 12-month post-procedure.
See also
  Status Clinical Trial Phase
Completed NCT03684161 - Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect
Completed NCT01120964 - Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol Phase 1/Phase 2
Completed NCT02914652 - The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects. Phase 4
Recruiting NCT05939713 - Cera™ VSD Occluder Post Market Clinical Follow-up
Recruiting NCT06298344 - The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease Early Phase 1
Recruiting NCT05688670 - Regional Anesthesia Following Pediatric Cardiac Surgery Phase 4
Completed NCT02138435 - Longterm Outcome After Ventricular Septal Defect Closure N/A
Recruiting NCT05253209 - A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects Phase 3
Completed NCT00556361 - Use of Ketamine Prior to Cardiopulmonary Bypass in Children Phase 2
Completed NCT05200910 - The Effect of Transcatheter VSD Closure on Children's Appetite, Hormones and Growth
Recruiting NCT03127748 - Cardiac Function After Transcatheter VSD Closure N/A
Enrolling by invitation NCT06214182 - Immune Heterogeneity Before and After Cardiopulmonary Bypass in Children
Active, not recruiting NCT04667455 - Improving Care for Children With Congenital Heart Disease. N/A
Completed NCT01313832 - The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension N/A
Active, not recruiting NCT04017975 - Optical Tissue Identification for Myocardial Architecture Phase 2
Completed NCT01915277 - A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics Phase 1
Recruiting NCT03941691 - A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure N/A
Completed NCT04859036 - The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters